Upregulation of hepatic LRP1 by rosiglitazone: A possible novel mechanism of the beneficial effect of thiazolidinediones on atherogenic dyslipidemia

Journal of Molecular Endocrinology

Volumn 49, Issue 3, 2012, Pages 165-174

  Moon, Jae Hoon ^a,b   Kim, Hyung Jun ^a   Kim, Hyun Min ^a   Yang, Ae Hee ^a   Lee, Byung Wan ^a   Kang, Eun Seok ^a   Lee, Hyun Chul ^a   Cha, Bong Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; GLUCOSE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA; ROSIGLITAZONE;

ANIMAL TISSUE; ASSAY; ATHEROSCLEROSIS; CELL STRAIN HEPG2; CULTURE MEDIUM; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; HUMAN CELL; LIVER LEVEL; LONG EVANS RAT; MALE; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REVIEW; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; DYSLIPIDEMIAS; HEP G2 CELLS; HUMANS; LIVER; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; RATS; THIAZOLIDINEDIONES;

EID: 84867910005     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-12-0119     Document Type: Review

References (32)

1. Ackerman Z, Oron-Herman M, Pappo O, Peleg E, Safadi R, Schmilovitz-Weiss H & Grozovski M 2010 Hepatic effects of rosiglitazone in rats with the metabolic syndrome. Basic & Clinical Pharmacology & Toxicology 107 663-668. (doi:10.1111/j.1742-7843. 2010.00553.x)
2. Assmann G & Schulte H 1992 Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. American Journal of Cardiology 70 10H-13H. (doi:10.1016/0002-9149(92)91084-H)
3. Basford JE, Wancata L, Hofmann SM, Silva RA, DavidsonWS, Howles PN & Hui DY 2011 Hepatic deficiency of low density lipoprotein receptor-related protein-1 reduces high density lipoprotein secretion and plasma levels in mice. Journal of Biological Chemistry 286 13079-13087. (doi:10.1074/jbc.M111.229369)
4. Bell DS, Al Badarin F & O'Keefe JH Jr 2011 Therapies for diabetic dyslipidaemia. Diabetes, Obesity and Metabolism 13 313-325. (doi:10.1111/j.1463-1326.2010.01342.x)
5. Berhanu P, Kipnes MS, Khan MA, Perez AT, Kupfer SF, Spanheimer RC, Demissie S & Fleck PR 2006 Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diabetes&Vascular Disease Research 3 39-44. (doi:10.3132/dvdr.2006.005)
6. Berneis K, Rizzo M, Stettler C, Chappuis B, Braun M, Diem P & Christ ER 2008 Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 9 343-349. (doi:10.1517/14656566.9.3.343)
7. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M & Cowley H 2000 Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metabolism and Disposition 28 772-780.
8. Fujioka Y & Ishikawa Y 2009 Remnant lipoproteins as strong key particles to atherogenesis. Journal of Atherosclerosis and Thrombosis 16 145-154. (doi:10.5551/jat.E598)
9. Fukushima H, Kugiyama K, Sugiyama S, Honda O, Koide S, Nakamura S, Kawano H, Soejima H, Miyamoto S, Yoshimura M et al. 2001 Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. American Journal of Cardiology 88 1370-1373. (doi:10.1016/S0002-9149(01)02115-4)
10. Fukushima H, Sugiyama S, Honda O, Koide S, Nakamura S, Sakamoto T, Yoshimura M, Ogawa H, Fujioka D & Kugiyama K 2004 Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. Journal of the American College of Cardiology 43 2219-2224. (doi:10.1016/j.jacc.2003.09.074)
11. Gauthier A, Vassiliou G, Benoist F & McPherson R 2003 Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry 278 11945-11953. (doi:10.1074/jbc.M212989200)
12. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT & Jacober SJ 2005 A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 1547-1554. (doi:10.2337/diacare.28.7.1547)
13. GordonDJ, ProbstfieldJL, GarrisonRJ, NeatonJD, CastelliWP, Knoke JD, Jacobs DR Jr, Bangdiwala S & Tyroler HA 1989 High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 8-15. (doi:10.1161/01.CIR.79.1.8)
14. Hanefeld M 2009 The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism 11 742-756. (doi:10.1111/j.1463-1326.2009.01048.x)
15. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E & Spiegelman BM 2000 Degradation of the peroxisome proliferatoractivated receptor gamma is linked to ligand-dependent activation. Journal of Biological Chemistry 275 18527-18533. (doi:10.1074/jbc.M001297200)
16. Herz J & Strickland DK 2001 LRP: a multifunctional scavenger and signaling receptor. Journal of Clinical Investigation 108 779-784. (doi:10.1172/JCI13992)
17. Hong H, Liu LP, Liao JM, Wang TS, Ye FY, Wu J, Wang YY, Wang Y, Li YQ, Long Y et al. 2009 Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice. Neuropharmacology 56 1054-1059. (doi:10.1016/ j.neuropharm.2009.03.001)
18. Igarashi M, Hirata A, Yamaguchi H, Jimbu Y & Tominaga M 2008 Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. Journal of Atherosclerosis and Thrombosis 15 34-40. (doi:10.5551/jat.E528)
19. Imke C, Rodriguez BL, Grove JS, McNamara JR, Waslien C, Katz AR, Willcox B, Yano K & Curb JD 2005 Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study Arteriosclerosis, Thrombosis, and Vascular Biology 25 1718-1722. (doi:10.1161/01.ATV.0000173310.85845.7b)
20. Innerarity TL, Pitas RE & Mahley RW 1979 Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. Journal of Biological Chemistry 254 4186-4190.
21. Laatsch A, Merkel M, Talmud PJ, Grewal T, Beisiegel U & Heeren J 2009 Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. Atherosclerosis 204 105-111. (doi:10.1016/ j.atherosclerosis.2008.07.046)
22. Merkel M 2009 Diabetic dyslipoproteinemia: beyond LDL. Deutsche Medizinische Wochenschrift 134 1067-1073. (doi:10.1055/s-0029-1222571)
23. Moon JH, Kim HJ, Yang AH, Kim HM, Lee BW, Kang ES, Lee HC & Cha BS 2011 The effect of rosiglitazone on LRP1 expression and amyloid beta uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. International Journal of Neuropsychopharmacology 15 135-142. (doi:10.1017/s1461145711001611)
24. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M & Neuvonen PJ 2003 Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46 1319-1323. (doi:10.1007/s00125-003-1181-x)
25. Rohlmann A, Gotthardt M, Hammer RE & Herz J 1998 Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. Journal of Clinical Investigation 101 689-695. (doi:10.1172/JCI1240)
26. Santos RD 2009 Commentary on the study of Laatsch et al. "Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance". Atherosclerosis 204 112-113. (doi:10.1016/j.atherosclerosis.2008.10.018)
27. Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM & Wilson PW 2002 Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 25 989-994. (doi:10.2337/diacare.25.6.989)
28. Taniguchi A, Fukushima M, Sakai M, Miwa K, Makita T, Nagata I, Nagasaka S, Doi K, Okumura T, Fukuda A et al. 2000 Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care 23 1766-1769. (doi:10.2337/diacare.23.12.1766)
29. van Wijk JP, de Koning EJ, Castro Cabezas M & Rabelink TJ 2005 Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 28 844-849. (doi:10.2337/diacare.28.4.844)
30. Willnow TE, Sheng Z, Ishibashi S & Herz J 1994 Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 264 1471-1474. (doi:10.1126/science.7515194)
31. Willnow TE, Armstrong SA, Hammer RE & Herz J 1995 Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. PNAS 92 4537-4541. (doi:10.1073/pnas.92.10.4537)
32. Yang SJ, Choi JM, Chae SW, KimWJ, Park SE, Rhee EJ, LeeWY, Oh KW, Park SW, Kim SW et al. 2011 Activation of peroxisome proliferatoractivated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats. PLoS ONE 6 e17057. (doi:10.1371/journal.pone.0017057)